Moreover, approaches like CRISPR-dCas9-mediated astrocyte-to-neuron conversion [181] and AAV-mediated delivery of anti-tau single-chain antibodies (scFvs) [182] have shown promise in reducing pathological tau accumulation in tauopathy models [183]. This evidence concerns the gene MAPT and tauopathy.